Concepedia

Martin Rimmer

MR

Statistics

Publications

4

Citations

235

H-Index

4

Active since

1996

Affiliations

AstraZeneca (United Kingdom)(Current)

University of Sheffield

AstraZeneca (United States)

Martin Rimmer is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and bone metabolism.

Publications per year

1996–2012

4

Publications

4

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

R.A. Hannon, Glen Clack, Martin Rimmer et al. · Journal of Bone and Mineral Research · 2009 · 110 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Use of Cold Therapy in the Postoperative Management of Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction

Dennis J. Edwards, Martin Rimmer, Greg Keene · The American Journal of Sports Medicine · 1996 · 77 citations

Medicine, Orthopaedic Surgery, Surgery +7

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

R.A. Hannon, Richard D. Finkelman, Glen Clack et al. · Bone · 2012 · 31 citations

Medicine, Oncology, Pharmacology +15

Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma

Narinder Chopra, Michael Williams, Martin Rimmer et al. · Respiratory Medicine · 2005 · 17 citations

Medicine, Pediatrics, Pharmacology +12

1–4 of 4